2-(7-Methoxynaphthalen-1-yl)ethanamine

We are 2-(7-Methoxynaphthalen-1-yl)ethanamine CAS:138113-09-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:   2-(7-Methoxynaphthalen-1-yl)ethanamine
CAS.NO:138113-09-4
Synonyms:
2-(7-methoxynaphthalen-1-yl)ethanamine

Molecular Formula: C13H15NO
Molecular Weight: 201.26400

Physical and Chemical Properties:
Density: 1.094g/cm3
Boiling point: 353.567ºC at 760 mmHg
Melting point: /
Flash point: 175.306ºC
Refractive index: 1.611

Specification:
Appearance: White Crystal Solid
Purity:≥99%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage: Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application:
Intermediates of Agomelatine  CAS:138112-76-2

2-(7-Methoxynaphthalen-1-yl)ethanamine


Related News: At the same time, experts said that API companies need to increase investment in environmental protection, carry out industrial upgrades, improve processes, improve pollution treatment capabilities, and then achieve sustainable development in the future, and seize structural opportunities.Clorhidrato de 2-clorometil-3-metil-4- (3-metoxipropoxi) piridina CAS:153259-31-5 The policy-oriented emphasis on the medical and pharmaceutical industries and the direct support for the chemical raw material pharmaceutical industry have created a good political environment for the development of related enterprises and laid the foundation for the rapid development of the chemical raw material pharmaceutical industry. The good development prospects of the chemical raw material pharmaceutical industry will be passed directly to the upstream raw material industry, which will help stimulate the demand for the pharmaceutical intermediate market.cis-4,7,10,13,16,19-Docosahexaenoic acid ethyl ester CAS:84494-72-4 In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.1198396-39-2 In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity.

Related Products
Product Name
Cetrorelix acetate View Details
1-IODO-4,4,4-TRIFLUOROBUTANE View Details
5-Bromo-3-nitro-2-pyridinol View Details
4-Fluoroanisole manufacturer Syn-HYCAN manufacturer 3-Fluoro-4-methoxyaniline manufacturer 3,5-Difluoropyridine-4-carboxylic acid manufacturer 2-Propylimidazole manufacturer